Table 1.
Prognostic significance of TAMs and relevant markers in different human tumor types.
| Tumor Type | Markers of TAMs | Prognostic Impact | References |
|---|---|---|---|
| Glioma | CD68, CD163, CD204 | Bad | [73] |
| IBA, CD204 | Bad | [74] | |
| CD163/CCL3 ratio | Bad (if high ratio) | [75] | |
| CD68, CD163/AIF ratio | Bad (if high ratio) | [76] | |
| Mesothelioma | CD68 | Bad | [69,70] |
| CD163 | Bad | [72] | |
| Lung cancer (NSCLC) | CD68 | Good (in tumor islets/bad in tumor stroma) | [61] |
| CD68/iNOS (for M1); CD68/CD163 (for M2) |
Bad (if M2 > M1) | [77] | |
| Pancreatic cancer | CD68, CD204 | Bad | [78] |
| Breast cancer | CD163 | Bad | [79] |
| CD68, CD163 | Bad | [80,81] | |
| iNOS | Good (if together with high CD8+ cells) | [17] | |
| Colorectal cancer | CD68 | Good (at the invasive front) | [82,83] |
| Wnt5a, CD68 | Bad | [84] | |
| Melanoma | CD68, CD163 | Bad (CD163 at tumor stroma and CD68 at invasive front) | [85] |
| Bladder cancer | CD68 | Bad | [86] |
TAM: tumor-associated macrophages; NSCLC: non-small-cell lung cancer.